Kira S. Sheinerman disclosed beneficial ownership of 51.56% of Niki BioSolutions, Inc.’s common stock. The stake resulted from the July 20, 2026 merger in which Aptorum domesticated and renamed itself Niki BioSolutions, with shares issued as non-cash consideration. The position gives Sheinerman significant governance rights and influence at the newly listed Nasdaq company.

Investor Intent

Sheinerman received the shares solely as merger consideration and entered into a Stockholders Agreement with Niki BioSolutions. Under this agreement, she “may designate two nominees” to the board while she owns at least 36% of the stock, and one nominee while she owns at least 25%, and she will vote with the board’s nominating committee for other directors until the 2027 annual meeting.

While she holds at least 25%, certain major corporate actions “require the prior written consent” of Sheinerman. The agreement also restricts transfers of the covered shares for six months after it took effect.

Investor's Background

Kira S. Sheinerman is a U.S. biotech executive and a co-founder of DiamiR Biosciences, where she focused on diagnostics for neurodegenerative diseases. She serves as a director of Niki BioSolutions, Inc. following the merger. Her investment approach centers on building and guiding early-stage life sciences companies through key strategic milestones.

Original SEC Filing: Niki BioSolutions, Inc. [ NIKI ] - SCHEDULE 13D - Jul. 24, 2026